Liraglutide in Type 1 Diabetes

NCT01612468 on ClinicalTrials.gov · last registry update 2016-01-27

Finished February 2015, after enrolling 100 people. Primary outcome, as filed: Change in HbA1c. liraglutide is approved in the US, but not for type 1 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Steno Diabetes Center Copenhagen
Sponsor type: Other
Enrollment: 100
Started: 2012-06
Primary completion: 2015-02 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in HbA1c

Conditions studied

Diabetes Mellitus, Type 1 · Overweight

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.